The Week in Review: Nov 2 – Nov 9, 2018

Friday, Nov 9, 2018 News Recap: Gilead Presents Latest Data from Viral Hepatitis Research Programs at The Liver Meeting® 2018 Gilead Sciences announced results from studies investigating Epclusa in chronic HCV patients with severe renal impairment undergoing dialysis and Harvoni in pediatric HCV patients aged three to five years. As well there was data from Gilead’s HBV cure development program. High Prevalence of Cirrhosis in Adults with Chronic...

High Prevalence of Cirrhosis in Adults With Chronic HBV at a Safety-Net Hospital

Of adults with chronic hepatitis B virus (HBV) infection seen at a safety-net hospital, nearly 30% had cirrhosis at initial presentation, with older male patients being at the highest risk, according to a retrospective study published in the Journal of Clinical and Experimental Hepatology. Cirrhosis is a serious consequence of HBV infection that is associated with a financial burden of $13 billion in the United States. Delays in HBV and cirrhosis diagnosi

Efficacy of Direct-Acting Antivirals for HCV Clearance in Older Adults

Data published in the Journal of the American Geriatrics Society suggest direct-acting antivirals (DAAs) are safe and effective at achieving a sustained virologic response in older adults with hepatitis C virus (HCV)-related fibrosis or cirrhosis. HCV clearance is essential in improving disease outcomes in the general population, but data on reducing liver-related complications and increasing life expectancy in older adults are limited. The researchers

The Week in Review: August 11 – August 18, 2017

Friday, August 18, 2017 Canada Great news in Canada. Two new drug regimens have been approved:  Vosevi from Gilead is a pangenotypic for retreatment of those who have failed previous DAA therapy Gilead Receives Approval in Canada for VOSEVI™ (Sofosbuvir/Velpatasvir/Voxilaprevir) for Re-treatment of Certain Patients with Chronic Hepatitis C Virus (HCV) Infection. And MAVIRET from AbbVie is the first and only 8-week, pan-genotypic treatment for hepatit...

Direct-acting Antivirals Effective in Older Patients with Hepatitis C

Treatment of hepatitis C virus (HCV) with sofosbuvir-based direct acting antivirals (DAAs) was recently found as effective and well-tolerated in elderly patients as it was in younger patients in previous development trials. "Historically, older patients have been underrepresented in studies evaluating the efficacy and safety of HCV treatment due to poor tolerability and suboptimal response to interferon-based regimens," the researchers wrote. Satapathy

Hep C Treatments Can Cause Adverse Effects in Older Patients

SAN FRANCISCO — Direct-acting antiviral medications can be effective in older patients with hepatitis C, but adverse reactions are common and the adjustment of other medications is often required, new research suggests."We need more data about these new treatments in the elderly," said Berta Pernas, from Corunna University Hospital in Spain."I think we can treat these patients, but caution for interactions and adverse events is required," she said here at